Votrient approved to treat advanced soft tissue sarcoma

Share this article:
Votrient Approved to Treat Advanced Soft Tissue Sarcoma
Votrient Approved to Treat Advanced Soft Tissue Sarcoma

(HealthDay News) -- Votrient (pazopanib) has been approved by the U.S. Food and Drug Administration to treat people with advanced soft tissue sarcoma who have received previous chemotherapy.

This type of tumor originates in soft tissue such as a muscle, fat, or fibrous tissue. About 10,000 cases of soft tissue sarcoma are reported each year in the United States.

Votrient works by inhibiting angiogenesis, the production of new blood vessels that fuel tumor growth. The drug's safety and effectiveness were evaluated in clinical studies involving 369 people with soft tissue sarcoma who had undergone chemotherapy. Among people who took Votrient, the disease didn't progress for an average of 4.6 months, compared to 1.6 months among people who took an inactive placebo.

The most common side effects of Votrient included fatigue, diarrhea, nausea, weight loss, high blood pressure, and decreased appetite. The drug's label will carry a "black box" warning of the potential for severe liver damage, which could be fatal. People who are given the drug should have their liver function monitored, the agency said.

Votrient was first approved in October 2009 to treat advanced kidney cancer. The drug is marketed by GlaxoSmithKline, based in Research Triangle Park, N.C.

More information

Medline Plus has more about this drug.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Poor staging linked to mortality in bladder cancer

Poor staging linked to mortality in bladder cancer

In cases of bladder cancer, omission of muscle in specimen or its mention in pathology report is linked to increased mortality.

Daily aspirin may lower mortality in nonmetastatic prostate cancer

Daily aspirin may lower mortality in nonmetastatic prostate ...

Even a small daily dose of aspirin may help lower mortality among men with nonmetastatic prostate cancer, according to research.

Irinotecan plus bevacizumab ups outcome for metastatic colorectal cancer (CRC)

Irinotecan plus bevacizumab ups outcome for metastatic colorectal ...

Findings show benefits compared with FOLFIRI for patients with untreated metastatic disease.